Pdr

OCU410 Phase 2 Armada top line results.

#OCU410 Phase 2 ArMaDa topline results show: • 31% ↓ GA lesion growth at 12 months vs. control • ~2X treatment effect vs. approved therapies • EZ preservation + favorable safety A one-and-done approach to reduce treatment burden. 🔗bit.ly/4c19g2f #GeographicAtrophy

Elaynna, an #OCU410ST trial participant, describes the procedure as seamless and the team as supportive after completing treatment for #Stargardtdisease. Now in Phase 2/3, GARDian3 is studying its potential to slow or stop progression. Phase 1 results: bit.ly/4c1rLSI

With the successful completion of enrollment in the GARDian3 Phase 2/3 pivotal trial for Stargardt disease, Ocugen expects to file BLA by mid-2027. Read more: bit.ly/4bLcNld #Stargardt #GeneTherapy #InheritedRetinalDiseases #BlindnessDiseases

One step closer to serving Stargardt patients! Big thanks to our dedicated Ocugen team.

Our one-time gene therapies target 100s of mutations and address the $132B annual burden of #visionloss. “Probably 100 years from now, they’ll say #genetherapy was one of the greatest discoveries of the 21st century.” – CEO @drsmusunuri in @PharmaVoice bit.ly/4sEc6A1

On #DoctorsDay, we thank the retinal surgeons advancing modifier gene therapy through their work in our clinical trials and serving as our advisors. Your work brings hope to patients facing major blindness diseases where few or no options exist. #GeneTherapy #Biotech

@TyWeezy7 You haven’t been following for very long if you think I’m going to wildly speculate what the future PPS will be when only the market will dictate that.

@Pdr_US Guessing isn’t knowing. Relax, I’m on the same side here.

$OCGN The next step for #OCU400, is to complete the manufacturing process validation, which will be essential in moving from clinical to commercial scale manufacturing. This is a #Ocugen publication from Dec 2025, highlighting the integration of Artificial Intelligence being pivotal with this process. It will be interesting to see what developments will be uncovered leading up to the validation, mid year. pubmed.ncbi.nlm.nih.gov/41415583/

Then why ask if you already think you know the answer? No one knows. More than approval comes into play when evaluating stock price. What partnerships lead to the completion and launch. How many public offerings were required. Did the company sell rights to certain patents, Is there a cut in profits, and what is the projected first quarter of revenue. Come back and answer all these before you can throw shade. No one knows these answers, including the various analysts.

@Pdr_US Lmao. Far from early buddy. I’ll go with 6-8.00

During #WorldOptometryWeek, we recognize the power of collaboration in expanding access to eye care. At Ocugen, we are driving gene therapy innovation for major blindness diseases to help address critical unmet needs in vision care. @WorldCouncilOpt #EyeHealth #GeneTherapy

@TyWeezy7 Too early to speculate, and still a long road ahead.

@Pdr_US Guesses on price point after approval of 400?

$OCGN Clear path to $10 before 2027? It will be very interesting to see whether this will actually happen before the very anticipated BLA submission this year. One can only hope, for investors and patients alike. merlintrader.com/ocugen-inc-ocg…

$OCGN Ocugen, Inc. (OCGN) PT Raised to $12 at Noble Capital from $8

$OCGN: HC Wainwright & Co. Raises Price Target to $10.00, Maintains Buy Rating | OCGN Stock News gurufocus.com/news/8741264/o…

Ocugen moving AMD-linked vision loss gene therapy to Phase III $OCGN firstwordpharma.com/story/7146766

Today, CEO @drsmusunuri shares encouraging 12-month Phase 2 results for #OCU410 in GA, showing impact on lesion growth and visual function. A one-time gene therapy approach with potential to shift the landscape and address unmet needs.   Read more: bit.ly/4lLGXYV

Ocugen will host a live webcast Mar 24 at 8 a.m. EDT on Phase 2 ArMaDa data for #OCU410 in GA, led by KOLs Lejla Vajzovic, MD, and Jay Chhablani, MD. Don’t miss key insights into advancements in modifier gene therapy for retinal disease. Details: bit.ly/4uJ8GgG

$OCGN Funding Announcement: On March 12, 2026, Ocugen, Inc. reported that an institutional investor purchased 10,000,000 shares of common stock for $15 million after partially exercising their warrants, extending the company's cash runway into Q1 2027. stockinsights.ai/us/OCGN/8-K/ca…

$OCGN Nice close. VWAP ends at 2.55, 18M volume. Held above all daily MAs 👍